Search research articles
Contact Us
Filters
Showing results (451-460 of 510) with videos related to
Page
of 51
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2022
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i><sup></sup> Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, et al.
Cancer Research
|
November 7, 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
A Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, et al.
Biorxiv : the Preprint Server for Biology
|
October 9, 2023
Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma
Zhuxuan Li, Xueqian Zhuang, Chun-Hao Pan, et al.
Future Oncology (London, England)
|
November 8, 2024
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study
Lyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2011
[(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells
Cathy C Zhang, Zhengming Yan, Wenlin Li, et al.
Anticancer Research
|
July 31, 2013
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity
Joshua E Logan, Nikayeh Mostofizadeh, Amrita J Desai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 11, 2010
PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity
Cathy C Zhang, Zhengming Yan, Qin Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 5, 2010
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth
Brion W Murray, Chuangxing Guo, Joseph Piraino, et al.
The New England Journal of Medicine
|
December 22, 2022
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated <i>KRAS</i> G12C
Rona Yaeger, Jared Weiss, Meredith S Pelster, et al.
Cancer Discovery
|
August 6, 2021
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Kwan Ho Tang, Shuai Li, Alireza Khodadadi-Jamayran, et al.
Page
of 51
Search research articles
Search
Showing results (451-460 of 510) with videos related to
Sort By:
Page
of 51
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2022
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i><sup></sup> Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, et al.
Cancer Research
|
November 7, 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
A Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, et al.
Biorxiv : the Preprint Server for Biology
|
October 9, 2023
Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma
Zhuxuan Li, Xueqian Zhuang, Chun-Hao Pan, et al.
Future Oncology (London, England)
|
November 8, 2024
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study
Lyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2011
[(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells
Cathy C Zhang, Zhengming Yan, Wenlin Li, et al.
Anticancer Research
|
July 31, 2013
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity
Joshua E Logan, Nikayeh Mostofizadeh, Amrita J Desai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 11, 2010
PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity
Cathy C Zhang, Zhengming Yan, Qin Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 5, 2010
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth
Brion W Murray, Chuangxing Guo, Joseph Piraino, et al.
The New England Journal of Medicine
|
December 22, 2022
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated <i>KRAS</i> G12C
Rona Yaeger, Jared Weiss, Meredith S Pelster, et al.
Cancer Discovery
|
August 6, 2021
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Kwan Ho Tang, Shuai Li, Alireza Khodadadi-Jamayran, et al.
Page
of 51